• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters1
Displaying 129-143 of 313 results

2066 Exhibit: Exhibit 2066 Erick H Turner, How to access and process FDA drug approval packages for use in research, BMJ 2013 served August 30, 2019

Document IPR2019-00207, No. 2066-138 Exhibit - Exhibit 2066 Erick H Turner, How to access and process FDA drug approval packages for use in research, BMJ 2013 served August 30, 2019 (P.T.A.B. De...
See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/257748574 How to access and process FDA drug approval packages for use in research ArticleinBMJ (online) · December 2012 DOI: 10.1136/bmj.f5992
1 author: Erick H Turner Oregon Health and Science University
2,054 Some of the authors of this publication are also working on these related projects: OpenTrialsFDA: Unlocking the FDA trove: Making unbiased clinical trial data accessible View project All content following this page was uploaded by Erick H Turner on 17 July 2016.
How to access and process FDA drug approval packages for use in research FDA databases contain valuable information on unpublished studies, but it can be difficult to find.
This article explains where to look and provides tips on how to make documents easier to use associate professor
cite Cite Document
Analyze

1076 Exhibit: USPN 9,161,926

Document IPR2019-00207, No. 1076-134 Exhibit - USPN 9,161,926 (P.T.A.B. Nov. 1, 2019)
Subject compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin.
It has been used to treat skin diseases characterized by the abnormal 15 infiltration of neutrophils, such as Dermatitis herpetiformis, linear IgA dermatosis, pustular psoriasis, pyoderma gan grenosum, acne vulgaris, and Sweet's Syndrome.
Skin conditions that can be treated using some com positions, products and methods described herein include, but are not limited to, acne, rosacea, folliculitis, perioral derma titis, photodamage, skin aging, psoriasis, ichtiosis, atopic der- 40 matitis, treatment of chronic wounds, bed sores, keratosis piralis, scars, including surgical and acne scars, sebaceous cysts, inflammatory dermatoses, post inflammatory hyper pigmentation, eczema, xerosis, pruritis, lichen planus, nodu lar prurigo, eczema, and miliaria.
Example 1 Table !lists two formulations (containing equivalent levels of diethylene glycol monoethyl ether) that show the impact of 25 acrylamide/sodium acryloyldimethyltaurate copolymer based thickener on dapsone particle size.
Additional examples containing alternate neutralizer Materials Anti-oxidants and chelating agents such as sodium met abisulfite, citric acid and EDTA were added to formulations to help slow down or completely stop any impurity formation.
cite Cite Document
Analyze

1054 Exhibit: FDA IIG Field Descriptions

Document IPR2019-00207, No. 1054-115 Exhibit - FDA IIG Field Descriptions (P.T.A.B. Nov. 1, 2019)
Log in to see more
cite Cite Document
Analyze

1061 Exhibit: Aczone Gel 75%

Document IPR2019-00207, No. 1061-119 Exhibit - Aczone Gel 75% (P.T.A.B. Nov. 1, 2019)
Log in to see more
cite Cite Document
Analyze

1038 Exhibit: Proposed Joint Pretrial Order Part 1

Document IPR2019-00207, No. 1038-101 Exhibit - Proposed Joint Pretrial Order Part 1 (P.T.A.B. Oct. 18, 2019)
Log in to see more
cite Cite Document
Analyze

1037 Exhibit: Email dated October 8, 2019 from Tyler Liu to trialsusptogov requesting authorization to file a motion for additional discovery

Document IPR2019-00207, No. 1037-100 Exhibit - Email dated October 8, 2019 from Tyler Liu to trialsusptogov requesting authorization to file a motion for additional discovery (P.T.A.B. Oct. 18, 2019)
Log in to see more
cite Cite Document
Analyze

2028 Exhibit: Exhibit 2028 Piette et al 2008

Document IPR2019-00207, No. 2028-59 Exhibit - Exhibit 2028 Piette et al 2008 (P.T.A.B. Aug. 9, 2019)
Log in to see more
cite Cite Document
Analyze

2019 Exhibit: Exhibit 2019 James 2009

Document IPR2019-00207, No. 2019-50 Exhibit - Exhibit 2019 James 2009 (P.T.A.B. Aug. 9, 2019)
Log in to see more
cite Cite Document
Analyze

2014 Exhibit: Exhibit 2014 Fabbrocini et al 2011

Document IPR2019-00207, No. 2014-45 Exhibit - Exhibit 2014 Fabbrocini et al 2011 (P.T.A.B. Aug. 9, 2019)
Log in to see more
cite Cite Document
Analyze

2036 Exhibit: Exhibit 2036 Thiboutot et al 2009

Document IPR2019-00207, No. 2036-67 Exhibit - Exhibit 2036 Thiboutot et al 2009 (P.T.A.B. Aug. 9, 2019)
Log in to see more
cite Cite Document
Analyze

2008 Exhibit: Exhibit 2008 Ahluwalia Intl Publ No WO 2011014627

Document IPR2019-00207, No. 2008-39 Exhibit - Exhibit 2008 Ahluwalia Intl Publ No WO 2011014627 (P.T.A.B. Aug. 9, 2019)

cite Cite Document
Analyze

2056 Exhibit: Exhibit 2056 Curriculum Vitae of Dr Leon Kircik 2019

Document IPR2019-00207, No. 2056-87 Exhibit - Exhibit 2056 Curriculum Vitae of Dr Leon Kircik 2019 (P.T.A.B. Aug. 9, 2019)

cite Cite Document
Analyze

2027 Exhibit: Exhibit 2027 Mills et al 1986

Document IPR2019-00207, No. 2027-58 Exhibit - Exhibit 2027 Mills et al 1986 (P.T.A.B. Aug. 9, 2019)

cite Cite Document
Analyze

2042 Exhibit: Exhibit 2042 Aczone 5% Medical Review

Document IPR2019-00207, No. 2042-73 Exhibit - Exhibit 2042 Aczone 5% Medical Review (P.T.A.B. Aug. 9, 2019)

cite Cite Document
Analyze

2038 Exhibit: Exhibit 2038 Titus et al 2012

Document IPR2019-00207, No. 2038-69 Exhibit - Exhibit 2038 Titus et al 2012 (P.T.A.B. Aug. 9, 2019)

cite Cite Document
Analyze
<< 1 2 3 4 5 ... 9 10 11 12 13 ... >>